FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67059
News■ Unclear/unknown
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 11:15 UTC
LAST UPDATE2026-10-06 11:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Phase 1 completion for a private inhaler platform is early-stage and not yet market-moving.
Early clinical milestone, years from revenue
CATALYST TO WATCH
Phase 2/3 trial initiation and data
MAIN RISK
Later-stage trials may fail
FULL DISPATCH
SUNRISE, Fla., Oct. 6, 2026 /PRNewswire/ -- TranspireBio Holdings Inc., an integrated U.S.-based clinical-stage, biopharmaceutical company advancing inhaled therapeutics for respiratory and systemic diseases, today announced the successful completion of a pivotal Phase 1 pharmacokinetic...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results2026-10-06 11:30 UTC
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results2026-10-06 11:30 UTC
→CORRELATIONshares Healthcare
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs2026-10-06 11:30 UTC
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs2026-10-06 11:30 UTC
→CORRELATIONshares Healthcare
Notre Dame researchers are developing AI technology to interpret nonverbal communication2026-10-06 12:02 UTC
Notre Dame researchers are developing AI technology to interpret nonverbal communication2026-10-06 12:02 UTC
→CORRELATIONshares Healthcare
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
→CORRELATIONshares Healthcare
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
→CORRELATIONshares Healthcare
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.